SG11201901583WA - Anti-ctla4 and anti-pd-1 bifunctional antibody, pharmaceutical composition thereof and use thereof - Google Patents

Anti-ctla4 and anti-pd-1 bifunctional antibody, pharmaceutical composition thereof and use thereof

Info

Publication number
SG11201901583WA
SG11201901583WA SG11201901583WA SG11201901583WA SG11201901583WA SG 11201901583W A SG11201901583W A SG 11201901583WA SG 11201901583W A SG11201901583W A SG 11201901583WA SG 11201901583W A SG11201901583W A SG 11201901583WA SG 11201901583W A SG11201901583W A SG 11201901583WA
Authority
SG
Singapore
Prior art keywords
bifunctional antibody
ctla4
pharmaceutical composition
ctla
targets
Prior art date
Application number
SG11201901583WA
Inventor
Baiyong Li
Yu Xia
Zhongmin Maxwell Wang
Peng Zhang
Original Assignee
Akeso Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akeso Pharmaceuticals Inc filed Critical Akeso Pharmaceuticals Inc
Publication of SG11201901583WA publication Critical patent/SG11201901583WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7019—Ischaemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)

Abstract

ANTI-CTLA AND ANTI-PD-1 BIFUNCTIONAL ANTIBODY, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF An anti-CTLA4(cytotoxic T lymphocyte associated antigen4)and anti-PD-1(programmed cell death 1)bifunctional antibody.a pharmaceutical composition thereof and use thereof.Particularly,the anti-CLTA4 and anti-PD-1 bifunctional antibody comprises afirst protein functional domain that targets PD-1 and a second protein functional domain that targets CTLA-4. The bifunctional antibody can bind to CTLA-4 and PD-1 specifically ,relieve immunosuppression of CTLA4 and PD-1 on an organism specifically,activate T lymphocytes,and thus has good application prospects. [Figure 52] 67
SG11201901583WA 2016-08-23 2017-08-22 Anti-ctla4 and anti-pd-1 bifunctional antibody, pharmaceutical composition thereof and use thereof SG11201901583WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610705624.2A CN106967172B (en) 2016-08-23 2016-08-23 The anti-PD-1 bifunctional antibody of anti-CTLA 4-, its medical composition and its use
PCT/CN2017/098466 WO2018036473A1 (en) 2016-08-23 2017-08-22 Anti-ctla4 and anti-pd-1 bifunctional antibody, pharmaceutical composition thereof and use thereof

Publications (1)

Publication Number Publication Date
SG11201901583WA true SG11201901583WA (en) 2019-03-28

Family

ID=59334390

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201901583WA SG11201901583WA (en) 2016-08-23 2017-08-22 Anti-ctla4 and anti-pd-1 bifunctional antibody, pharmaceutical composition thereof and use thereof

Country Status (14)

Country Link
US (2) US11578128B2 (en)
EP (1) EP3511346A4 (en)
JP (2) JP7425604B2 (en)
KR (1) KR102503084B1 (en)
CN (1) CN106967172B (en)
AU (1) AU2017317124A1 (en)
BR (1) BR112019003695A2 (en)
CA (1) CA3034850A1 (en)
EA (1) EA201990571A1 (en)
IL (1) IL264964B2 (en)
MX (1) MX2019002254A (en)
NZ (1) NZ751904A (en)
SG (1) SG11201901583WA (en)
WO (1) WO2018036473A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113501879A (en) * 2021-06-30 2021-10-15 拜盖特生物科技(上海)有限公司 Bifunctional antibody for relieving immunosuppression in tumor immune microenvironment, and application and preparation method thereof

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180040138A (en) 2015-07-13 2018-04-19 싸이톰스 테라퓨틱스, 인크. Anti-PD-1 antibodies, activatable anti-PD-1 antibodies, and methods of using them
EP4257613A3 (en) 2016-06-14 2023-12-13 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
CN106967172B (en) 2016-08-23 2019-01-08 康方药业有限公司 The anti-PD-1 bifunctional antibody of anti-CTLA 4-, its medical composition and its use
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
CN106977602B (en) * 2016-08-23 2018-09-25 中山康方生物医药有限公司 A kind of anti-PD1 monoclonal antibodies, its medical composition and its use
CN108866635B (en) * 2017-05-09 2021-11-26 安升（上海）医药科技有限公司 Multispecific protein medicine and library thereof, and preparation method and application thereof
US11421029B2 (en) 2017-09-01 2022-08-23 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Recombinant bispecific antibodies to PD-L1 and CTLA-4
KR20200091382A (en) * 2017-11-02 2020-07-30 시스트이뮨, 인코포레이티드 Bispecific antibodies and methods for their preparation and use
WO2019179421A1 (en) * 2018-03-19 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific pd-1/ctla-4 antibody molecules
CN110407942B (en) * 2018-04-27 2022-02-22 苏州康宁杰瑞生物科技有限公司 Single domain antibodies against KN044
CN115991787A (en) 2018-06-05 2023-04-21 江苏康宁杰瑞生物制药有限公司 Dimer and use thereof
CN110684113A (en) * 2018-07-06 2020-01-14 复旦大学 Bispecific antibody for resisting PD-1 antigen and c-Met antigen and construction method thereof
CN109762068A (en) * 2018-08-09 2019-05-17 源道隆（苏州）医学科技有限公司 A kind of single-gene bispecific antibody targeting CTLA4 and PD-1 and its application
CN109053895B (en) * 2018-08-30 2020-06-09 中山康方生物医药有限公司 Bifunctional antibody for resisting PD-1-VEGFA, pharmaceutical composition and application thereof
WO2020057610A1 (en) * 2018-09-20 2020-03-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific anti-ctla-4/pd-1 polypeptide complexes
WO2020057611A1 (en) * 2018-09-20 2020-03-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific ctla-4/pd-1 polypeptide complexes
CN111763261B (en) * 2019-04-02 2022-08-09 杭州尚健生物技术有限公司 Fusion protein and application thereof
CN112175087B (en) * 2019-07-02 2022-05-13 深圳市迈加瑞生物技术有限公司 Bispecific antibody for resisting CD4 and TGF beta, pharmaceutical composition and application thereof
EP3998286A4 (en) * 2019-07-11 2023-04-26 Wuhan Yzy Biopharma Co., Ltd. Tetravalent symmetric bispecific antibody
EP4008730A4 (en) * 2019-08-02 2023-09-06 Akeso Pharmaceuticals, Inc. Anti-ctla4-anti-pd-1 bispecific antibody and uses thereof
US20220267444A1 (en) 2019-08-02 2022-08-25 CTTQ-Akeso (ShangHai) Biomed. Tech. Co., Ltd. Anti-pd-1 antibody and medical use thereof
CN112442126B (en) * 2019-09-04 2022-07-29 杭州济元基因科技有限公司 Monoclonal antibody of anti-human CS1 antigen and CAR-T cell thereof
CN110563845A (en) * 2019-09-12 2019-12-13 滨州医学院 anti-IGSF 9 antibody, pharmaceutical composition and application thereof
BR112022010069A2 (en) 2019-11-25 2022-09-06 Akeso Biopharma Inc BIESPECIFIC ANTIBODY, ISOLATED NUCLEIC ACID MOLECULE, VECTOR, HOST CELL, CONJUGATE, KIT, USE OF BIESPECIFIC ANTIBODY AND PHARMACEUTICAL COMPOSITION
WO2021110106A1 (en) * 2019-12-04 2021-06-10 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Bispecific fusion protein for tumor treatment
IL297432A (en) * 2020-04-22 2022-12-01 Akeso Biopharma Inc Anti-cd73-anti-pd-1 bispecific antibody and use thereof
WO2021213523A1 (en) * 2020-04-24 2021-10-28 信达生物制药(苏州)有限公司 Uses of combination of anti-pd-1 antibody and anti-ctla-4 antibody in preventing or treating cancer
CN113577255B (en) * 2020-04-30 2023-09-08 中国科学院上海药物研究所 Tumor nano vaccine, preparation method and application thereof
CN111944760A (en) * 2020-08-14 2020-11-17 广东先康达生物科技有限公司 Immune cell for secreting bi-specific antibody and application thereof
CN112079926A (en) * 2020-09-17 2020-12-15 北京华大蛋白质研发中心有限公司 Anti-human CTLA4 monoclonal antibody and application thereof
US20240018254A1 (en) * 2020-10-23 2024-01-18 Akeso Biopharma, Inc Anti-cd73 antibody and use thereof
CA3193662A1 (en) 2021-03-12 2022-09-15 Akeso Biopharma, Inc. Pharmaceutical combination containing anti-pd-1-anti-vegfa bispecific antibody, and use thereof
CN115073588B (en) * 2021-03-12 2024-06-18 中山康方生物医药有限公司 Method for improving safety of drugs containing immunoglobulin Fc fragment
US20240199741A1 (en) 2021-04-14 2024-06-20 Akeso Pharmaceuticals, Inc. Use of antibody in anti-tumor treatment
CN115873116A (en) 2021-09-29 2023-03-31 中山康方生物医药有限公司 anti-LAG 3 antibodies, pharmaceutical compositions and uses
WO2023143597A1 (en) * 2022-01-30 2023-08-03 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-ctla4/ox40 bispecific antibodies and uses thereof
WO2024051223A1 (en) 2022-09-09 2024-03-14 中山康方生物医药有限公司 Pharmaceutical composition and use thereof
CN116396392B (en) * 2023-01-17 2023-10-27 珠海重链生物科技有限公司 Antibody specific to digoxigenin and related application thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ES2367430T3 (en) 2002-12-23 2011-11-03 Wyeth Llc ANTIBODIES AGAINST PD-1 AND ITS USES.
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
US9029508B2 (en) 2008-04-29 2015-05-12 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
MX349463B (en) 2008-09-26 2017-07-31 Univ Emory Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor.
CN102822198B (en) * 2010-03-12 2016-08-31 艾伯维生物医疗股份有限公司 CTLA4 albumen and its purposes
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
PL2691112T3 (en) 2011-03-31 2018-09-28 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
SI2699264T1 (en) 2011-04-20 2018-08-31 Medimmune Llc Antibodies and other molecules that bind b7-h1 and pd-1
US9845356B2 (en) 2012-08-03 2017-12-19 Dana-Farber Cancer Institute, Inc. Single agent anti-PD-L1 and PD-L2 dual binding antibodies and methods of use
WO2014209804A1 (en) * 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
CN104250302B (en) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 The anti-antibody of PD 1 and its application
LT3081576T (en) * 2013-12-12 2019-10-25 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
MX2016008189A (en) * 2014-01-03 2016-09-29 Hoffmann La Roche Covalently linked helicar-anti-helicar antibody conjugates and uses thereof.
TWI681969B (en) 2014-01-23 2020-01-11 美商再生元醫藥公司 Human antibodies to pd-1
CN104974253A (en) * 2014-04-01 2015-10-14 上海中信国健药业股份有限公司 Anti-CTLA-4/PD-1 bispecific antibody as well as preparation method and application thereof
CN105296433B (en) * 2014-08-01 2018-02-09 中山康方生物医药有限公司 A kind of CTLA4 antibody, its medical composition and its use
CN104987421A (en) 2015-05-13 2015-10-21 北京比洋生物技术有限公司 Anti-CTLA-4 and PD-1 dual variable domain immunoglobulin
CN105175544B (en) * 2015-10-20 2021-04-09 安徽瀚海博兴生物技术有限公司 anti-PD-1 humanized monoclonal antibody and application thereof
CN105175545B (en) 2015-10-20 2019-01-25 安徽瀚海博兴生物技术有限公司 A kind of anti-PD-1 bifunctional antibody of anti-vegf-and its application
BR112018011781A2 (en) 2015-12-14 2018-12-04 Macrogenics Inc bispecific molecule having one or more epitope binding sites capable of immunospecific binding to (one) pd-1 epitope (s) and one or more epitope binding sites capable of immunospecific binding to (one) epitope (s) -4, and pharmaceutical composition
CN105754990A (en) * 2016-01-29 2016-07-13 深圳精准医疗科技有限公司 Preparation method and application of PD-1/CTLA-4 (programmed death-1/cytotoxic T lymphocyte antigen-4) bispecific antibody
CN106967172B (en) 2016-08-23 2019-01-08 康方药业有限公司 The anti-PD-1 bifunctional antibody of anti-CTLA 4-, its medical composition and its use
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
CN106977602B (en) 2016-08-23 2018-09-25 中山康方生物医药有限公司 A kind of anti-PD1 monoclonal antibodies, its medical composition and its use

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113501879A (en) * 2021-06-30 2021-10-15 拜盖特生物科技(上海)有限公司 Bifunctional antibody for relieving immunosuppression in tumor immune microenvironment, and application and preparation method thereof

Also Published As

Publication number Publication date
US11578128B2 (en) 2023-02-14
CA3034850A1 (en) 2018-03-01
EP3511346A4 (en) 2020-04-29
IL264964A (en) 2019-04-30
WO2018036473A1 (en) 2018-03-01
BR112019003695A2 (en) 2019-06-04
KR102503084B1 (en) 2023-02-24
AU2017317124A1 (en) 2019-04-11
EP3511346A1 (en) 2019-07-17
KR20190052677A (en) 2019-05-16
JP2022130393A (en) 2022-09-06
CN106967172A (en) 2017-07-21
US20240010728A1 (en) 2024-01-11
JP2019533475A (en) 2019-11-21
EA201990571A1 (en) 2019-08-30
MX2019002254A (en) 2019-11-28
JP7425604B2 (en) 2024-01-31
NZ751904A (en) 2023-01-27
IL264964B2 (en) 2023-10-01
IL264964B1 (en) 2023-06-01
CN106967172B (en) 2019-01-08
US20190185569A1 (en) 2019-06-20

Similar Documents

Publication Publication Date Title
SG11201901583WA (en) Anti-ctla4 and anti-pd-1 bifunctional antibody, pharmaceutical composition thereof and use thereof
NZ734256A (en) Use of plinabulin in combination with immune checkpoint inhibitors
SG11201901584UA (en) Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof
SA518390862B1 (en) Anti - pd - l1 antibodies
PH12018500183A1 (en) Novel anti-pd-1 antibodies
MX2023004018A (en) Modulators of estrogen receptor proteolysis and associated methods of use.
AU2018258045A1 (en) Chimeric antibody/T-cell receptor constructs and uses thereof
ECSP19040905A (en) ANTI-TIM-3 ANTIBODIES TO COMBINE WITH ANTI-PD-1 ANTIBODIES
MX2021002312A (en) Anti-pd-1 and anti-vegfa bifunctional antibody, pharmaceutical composition thereof and use thereof.
AU2018260863A1 (en) Human IgG1 Fc region variants and uses thereof
CY1124190T1 (en) ANTI-CTLA4 MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, PHARMACEUTICAL COMPOSITION AND USE
PE20171180A1 (en) ANTI-PD-1 ANTIBODIES AND THEIR METHODS OF USE
HRP20220629T1 (en) Anti-cd73 antibodies and uses thereof
WO2013173820A3 (en) Bispecific scfv immunofusion (bif)
CA2886433C (en) Human monoclonal anti-pd-l1 antibodies and methods of use
WO2019009727A8 (en) Bispecific anti pd1-anti tim3 antibodies
MX2020008446A (en) Methods for treating cancer with anti pd-1 antibodies and anti ctla4 antibodies.
MX2021007274A (en) Bifunctional anti-pd-1/sirpa molecule.
MX2023002045A (en) Multi-paratopic anti-pd-1 antibodies and uses thereof.
EP3768719A4 (en) High affinity neutralizing monoclonal antibodies to programmed death ligand 1 (pd-l1) and uses thereof
WO2021074695A8 (en) PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
MX2021004226A (en) Combination therapy for cancer.
AR111193A1 (en) BIESPECTIFIC ANTIBODIES THAT BIND WITH HUMAN SCHEDULED DEATH CELL 1 (PD-L1) AND PROTEIN 3 CONTAINING IMMUNOGLOBULIN DOMAIN AND T-CELL MUCINE (TIM-3)
AU2019379261A8 (en) Pharmaceutical combination of anti-CEACAM6 and either anti-PD-1 or anti-PD-l1 antibodies for the treatment of cancer
MX2020009863A (en) Anti-cd137 antibodies for combination with anti-pd-l1 antibodies.